Clinical Trial Update: Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating early argipressin for managing norepinephrine-refractory vasoplegic shock in intensive care patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasoplegic Shock

Drugs mentioned

• Argipressin (vasopressin)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Patients With Norepinephrine-refractory Vasoplegic Shock | Phase 3 | Status: RECRUITING